Marlborough, MA, United States of America

Timothy A Lewis

This inventor holds 21 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Cancer Treatment. Top assignees: The Broad Institute, Inc., Bayer Pharma Aktiengesellschaft, Dana-Farber-Cancer Institute Inc.. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy A Lewis. Retrieved from https://idiyas.com/inventor/timothy-a-lewis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 9)

% Patents Active = 85.7

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 32(Granted Patents)

Location History:

Framingham, MA (US) (2002 - 2005)
Rowlette, TX (US) (2020)
Marlborough, MA (US) (2004 - 2024)
Cambridge, MA (US) (2018 - 2024)

Company Filing History:

16 out of 490

The Broad Institute, Inc.

patents

8 out of 387

Bayer Pharma Aktiengesellschaft

patents

7 out of 1,269

Dana-Farber-Cancer Institute Inc.

patents

4. 6 out of 12,269

Bayer Aktiengesellschaft

The General Hospital Corporation

Massachusetts Institute of Technology

patents

10. 1 out of 1,498

Rutgers, The State University of New Jersey

patents

11. 1 out of 22

Sam Houston State University

patents

12. 1 out of 1,430

The Brigham and Women's Hospital, Inc.

patents

13. 1 out of 5,644

The University of Texas System

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

Areas of Expertise:

Hyperproliferative Diseases

Cancer Patient Stratification

PDE3A Inhibitors

Dihydrooxadiazinones

Tuberculosis Treatment

Nystagmus Training

Asthma Treatment

Inflammatory Disorders

Thiazole-Based Inhibitors

Antioxidant Modulators

Hematological Cancers

Malaria Treatment

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427153 - 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases (2025-09-30),

2. 12258323 - Dihydrooxadiazinones (2025-03-25),

3. 12053476 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2024-08-06),

4. 11897867 - 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer (2024-02-13),

5. 11773070 - Dihydrooxadiazinones (2023-10-03),

6. 11427553 - Dihydrooxadiazinones (2022-08-30),

7. 11325913 - Compounds and methods for the treatment of malaria (2022-05-10),

8. 11142522 - Compounds, compositions and methods for cancer treatment (2021-10-12),

9. 11096934 - Compounds and methods useful for treating or preventing hematological cancers (2021-08-24),

10. 10966986 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2021-04-06),

11. 10839713 - Individual nystagmus simulated training experience (2020-11-17),

12. 10738055 - Compounds and methods for the treatment of malaria (2020-08-11),

13. 10301294 - Compounds for the treatment of tuberculosis (2019-05-28),

14. 10106502 - Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators (2018-10-23),

15. 10059711 - Compounds and methods for the treatment of malaria (2018-08-28),

Title: The Innovative Path of Inventor Timothy A Lewis

Introduction: Timothy A Lewis is a prolific inventor based in Marlborough, MA (US), known for his remarkable contributions to the field of pharmaceuticals and cancer treatment. With a total of 10 patents to his name, Lewis has been at the forefront of groundbreaking discoveries.

Latest Patents: Among his latest patents is the development of Dihydrooxadiazinones compounds, aimed at the treatment and prophylaxis of hyperproliferative diseases. Additionally, Lewis has pioneered methods for cancer patient stratification and treatment, utilizing biomarkers such as PDE3A, SLFN12, and CREB3L1 to identify drug sensitivity and personalize treatment approaches.

Career Highlights: Timothy A Lewis has notably worked with esteemed institutions such as The Broad Institute, Inc. and UCB S.A., where his expertise and innovative mindset have led to significant advancements in the pharmaceutical industry. His patent portfolio reflects his dedication to revolutionizing cancer treatment strategies.

Collaborations: Throughout his career, Timothy A Lewis has collaborated with accomplished individuals in the field, including Xiong Cai and Ralph Scannell. These collaborations have enhanced the impact of his research and propelled the development of groundbreaking pharmaceutical solutions.

Conclusion: In conclusion, Timothy A Lewis stands as a visionary inventor who continues to push the boundaries of innovation in pharmaceuticals and cancer treatment. His relentless pursuit of excellence and commitment to improving patient outcomes make him a standout figure in the industry.

Profile summary based on public USPTO records.